Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)

Trial Profile

Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms PROMISE
  • Most Recent Events

    • 12 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Mar 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
    • 09 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top